(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 29.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.47%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.58%.
Adc Therapeutics Sa's revenue in 2026 is $79,584,000.On average, 8 Wall Street analysts forecast ADCT's revenue for 2026 to be $10,460,707,925, with the lowest ADCT revenue forecast at $9,183,392,637, and the highest ADCT revenue forecast at $11,494,305,584. On average, 7 Wall Street analysts forecast ADCT's revenue for 2027 to be $13,277,440,280, with the lowest ADCT revenue forecast at $9,508,689,924, and the highest ADCT revenue forecast at $15,916,331,536.
In 2028, ADCT is forecast to generate $23,397,658,463 in revenue, with the lowest revenue forecast at $16,765,321,707 and the highest revenue forecast at $28,772,468,422.